key: cord-0918075-ptvsie6m
authors: Yin, Di; Ling, Sikai; Tian, Xiaolong; Li, Yang; Xu, Zhijue; Jiang, Hewei; Zhang, Xue; Wang, Xiaoyuan; Shi, Yi; Zhang, Yan; Da, Lintai; Tao, Sheng-ce; Wang, Quanjun; Xu, Jianjiang; Ying, Tianlei; Hong, Jiaxu; Cai, Yujia
title: A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities
date: 2020-05-15
journal: bioRxiv
DOI: 10.1101/2020.05.14.093054
sha: 2cd3b9c4a29e18712af4a7a4228d9e36219e5b7e
doc_id: 918075
cord_uid: ptvsie6m

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for which a vaccine is urgently needed to control its spreading. To facilitate the representation of a native-like immunogen without being infectious, here, we reported a SARS-CoV-2 vaccine candidate (designated ShaCoVacc) by incorporating spike-encoding mRNA inside and decorating spike protein on the surface of the virus simulating particles (VSPs) derived from lentiviral particles. We characterized the mRNA copy number, glycosylation status, transduction efficiency, and innate immune property of the new vaccine platform. Importantly, we showed the ShaCoVacc induced strong spike-specific humoral immune responses and potent neutralizing activities by a single injection. Additionally, we disclosed the epitopes of spike-specific antibodies using peptide microarray and revealed epitopes susceptible to specific neutralizing antibodies. These results support further development of ShaCoVacc as a candidate vaccine for COVID-19 and VSP may serve as a new vaccine platform for emerging infectious diseases.

basing on different platforms, i.e. mRNA, adenovirus, lentivirus, and plasmid DNA 6 . However, 23 published information regarding the neutralizing efficacy of each vaccine is still very limited except 24 an inactivated vaccine for which, however, multiple vaccinations are needed to get high EC50 titer 7, 8 . 25

In the past decades, numerous vaccine platforms have been approved for markets or clinical trials. 26

Live attenuated vaccines are weakened pathogens that induce strong humoral and cellular immune 27 response but also with infection risks especially for immune-compromised people 9,10 . Inactivated 28 vaccines are killed pathogens with intact structure and destroyed genetic materials -therefore, less 29 risky, but also less efficacy 9,10 . Protein subunit vaccine, viral vector vaccine, and nucleic acid vaccine 30 (DNA and mRNA) are generally safe, but difficult to reflect the conformational structure of viral 31 immunogen in its nature 11, 12 . Virus-like particles (VLPs) are hulk particles with the unique ability to 1 present viral spikes in their natural conformation and elicit conformation-dependent neutralizing 2 antibodies 13-16 . A closer mimicking of a pathogen would be a VLP with spikes on its surface and 3 antigen-encoding nucleic acids inside. It is still unknown which vaccine platform will actually work 4 for SARS-CoV-2, making the development of new vaccine platforms of great importance. As 5 neutralizing antibodies have been detected in convalescents of COVID-19 17-20 , a SARS-CoV-2 6 simulating vaccine may present the antigens to the immune systems in much the same way that it 7 would be presented by an authentic virus, thereby provoking a similar effective immune response. 8

In this study, we designed a candidate vaccine by encapsulating spike within and decorated onto the 9 surface of virus simulating particles (VSPs) derived from lentiviral particles in the form of mRNA 10 and protein, respectively, simulating the wild-type SARS-CoV-2. We hypothesized this could be 11 achieved by co-expression of a full-length spike during the production of mRNA-carrying lentiviral 12 particle which we have recently developed for time-restricted gene editing (Manuscript under 13 revision). To package the full-length spike mRNA into VSPs, we designed a spike construct 14 expressing the spike protein with 6X MS2 stem loop repeats on its transcripts which would allow the 15 spike mRNA to be packaged into VSPs via interaction with MS2 coat fused GagPol (Fig. 1a) . 16

Meanwhile, as an envelope protein, the spike protein would automatically assemble into the 17 membrane of virus simulating particles (Fig. 1b) . 18

To make sure high transcription and translation in the producer cells, we used a CMV promoter to 19 drive spike expression (Fig. 1a ). In addition, the spike sequence was codon-optimized and equipped 20 with a signal peptide from the human heavy chain of IgE to boost translation and immunogenicity 21 ( Fig. 1a ) 4 . We also introduced two proline substation mutations in the S2 of spike sequence which 22

have been reported to increase the expression of spike and enhance the production of neutralizing 23 antibodies ( Fig. 1a) 21, 22 . The resulting spike transcript contains a MS2 stem loop between the stop 24 codon and the polyA sequence so that it could be packaged into lentiviral particles via direct 25 interaction with its cognate MS2 coat protein localized in the N-terminus of GagPol polyprotein. As 26 VSV-G coated lentiviruses are efficiently taken up by antigen-presenting cells and show the high 27 immunogenicity of antigens 23 , we also included the VSV-G encoding plasmid (pMD.2G) in the 28 production process so that the surface of resulting VSPs will be covered by both spike and VSV-G 29 (Fig. 1b) . 30

To examine if spike mRNA has been packaged into lentiviral particle as designed, we performed RT-31 qPCR and found 3 or 4 copies of spike mRNA on average for each VSP (Fig. 1c) . To verify whether 32 spike proteins have been assembled into VSPs and their glycosylation status, we performed Western 1 blot on the lysates of VSP with integration-defective lentiviruses (IDLVs) as controls (Fig. 1d) . We 2 found successful decoration of spikes both with and without mutations on the VSPs while more 3 mutant spikes could be loaded. As glycosylation impacts the immunogenicity and immunodominance 4 of a vaccine 24 , we examined the glycosylation status of the spike on the surface of VSPs. Notably, 5 the S2 bands shifted downwards after PNGase F treatment indicating that the spikes on VSPs were 6 modified by N-linked glycosylations consistent with the resent finding for SARS-CoV-2 revealed by 7 mass spectrometric approach (Fig. 1d ) 25 . Next, we transduced VSPs to 293T cells and evaluated the 8 expression of spikes. We harvested the cells 36 hr postinfection without boiling the samples for 9

Western blot to avoid potential aggregation of the spike protein. 293T cells were not infected by 10 SARS-CoV-2 unless supplemented with hACE2 26 . Here, we still observed the expression of spikes 11 in 293T cells from VSPs suggesting that VSV-G were co-assembled into VSPs, thereby, broadened 12 their tropism (Fig. 1e ). We found two major bands for spikes which were likely glycosylated full-13 length singlet spike and its dimeric/trimeric forms (Fig. 1e) . Additionally, we confirmed the 14 expression of spike using confocal analysis of transfected or transduced 293T cells (Fig. 1f ). To 15 examine the innate immune property of VSP, we used THP-1 derived macrophages as a model of 16 nucleic sensing and found no significant increase of the type I interferon (IFN) and IFN-stimulated 17 genes ISG-15, and retinoic acid-inducible gene I (RIG-I) ( Fig. 1g-i) . As VSP-spike-mut incorporates 18 both mRNA and protein of spike more efficiently than the wild-type counterpart, we therefore chose 19 it as a vaccine candidate (designated ShaCoVacc) for in vivo evaluation. 20

To access the immunogenicity of ShaCoVacc, we injected the vaccine candidate to C57BL/6J mice 21 (n=6 for each group) via footpad (Fig. 2a) . We performed enzyme-linked immunosorbent assay 22 (ELISA) using the sera from mice two weeks after vaccination to get access to the spike-specific IgG. 23

As shown in Fig. 2b , we observed significant elicitation of the spike-specific IgG. To evaluate the 24 production of neutralizing antibodies, we performed the neutralizing assay using spike pseudotyped 25

HIV which encodes firefly luciferase -a well-established pseudovirus neutralization assay 27 . 26

Interestingly, a single injection of ShaCoVacc in our study induced an immediate and potent immune 27 responses against SARS-CoV-2 in contrast to an inactivated vaccine which required at least two or 28 three doses of injections ( Fig. 2c) 8 . We also adopted the spike pseudotyped lentivirus which encodes 29 GFP to transduce Huh-7 cells. We found pre-incubation with 1:40 diluted sera from vaccinated mice 30 almost completely abolished the fluorescence which was evident for placebo groups and positive 31 controls ( Fig. 2d) in line with Fig. 2c . Interestingly, sera from the vaccinated mice did not inhibit the 32 transduction of VSV-G pseudotyped lentivirus in Huh-7 cells indicating the neutralizing antibody is 1 spike-specific (Fig. 2d ). T cell immune response is usually important for the function of vaccines to 2 control virus infection 28 . However, in case of COVID-19, overproduction of cytokines has been 3 correlated with the disease severity 29 . Therefore, cellular immunity must be cautious for any SARS-4

CoV-2 vaccines. Here, we evaluated the T cell immune response here by simulating splenocytes with 5 a pool of spike-derived peptides. We did not found increased expression of IFN-γ and IL-2 suggesting 6 spike-specific cellular immune response was insignificant for ShaCoVacc ( Fig. 2e-f ). This is line 7 with a recent study with an inactivated SARS-CoV-2 vaccine which showed protection effects, but 8 found no notable changes in the percentages of lymphocytes and key cytokines in vaccinated 9 macaques 8 . Additionally, no weight loss caused by ShaCoVacc was found during the course of 10 vaccination suggesting no evident toxicity ( Supplementary Fig. 1) . 11

To dissect the linear epitope profile of the spike-specific antibodies in the vaccinated mice, we used 12 a newly developed peptide microarray which contains short peptides covering the full-length of a 13 spike. We found varying intensities of signals corresponding to certain spike peptides for the 14 vaccinated group while no signal was observed for the placebo treated mice (Fig. 2g) . We also 15 quantified the signal intensity for antibodies against the S1 domain and receptor-binding domain 16 (RBD), respectively. The sera from vaccinated mice elicited significantly high signals for both 17 domains echoing our ELISA analysis of spike-specific antibodies and neutralizing assays (Fig. 2h) . 18

To access to the panorama of epitopes, we made a heat map for of all vaccinated mice and found 19 epitope profiles for each vaccinated mouse were distinct ( Fig. 2i and Supplementary Table 1) . 20

However, we also found three epitopes (S2-22, S2-76, and S2-83) that were common for 66.7% of 21 the vaccinated mice. Interestingly, the S2-22 epitope also appeared in the majority of the 22 convalescents uncovered by our peptide microarray (manuscript in preparation). Antibody against 23 this epitope pulled from sera of convalescents has shown potent neutralizing activity 17 . Notably, S2-24 76 and S2-83 epitopes are conserved epitopes and shared by SARS-CoV and SARS-CoV-2 25 ( Supplementary Fig. 2) . 26

We further revealed five neutralization epitopes locating on RBD, the domain responsible for the host 27 receptor recognition. The identified antibodies targeting these sites, therefore, can potentially block 28 the virus entry efficiently (Fig. 2j) . Notably, former studies have shown that the murine 29 monoclonal/polyclonal antibodies that exhibit apparent binding to RBD from SARS-CoV exert no 30 neutralization activities against SARS-CoV-2, likely caused by their distinct structural features 30 . Our 31 findings thus pinpoint the key structural motifs in SARS-CoV-2-RBD that are susceptible to specific 32 neutralizing antibodies. Interestingly, we also identified S2-83 epitope (N1178-V1189) locating on 1 the HR2 region, which undergoes a dramatic refolding process during virus entry, leading to the 2 formation of a six-helix bundle structure that finally drives membrane fusion (Fig. 2h) . Considering 3 the critical role of HR2 and its high sequence conservation among different coronaviruses 4 ( Supplementary Fig. 2) , it is conceivable that antibody targeting to HR2 may potentially induce a 5 broad neutralizing activity against various coronaviruses. 6

In compensation to the traditional vaccine platforms, our study provided a new vaccine platform by 7 simulating coronavirus surface protein and internal nucleic acids, therefore, combining features of 8 inactivated vaccines and mRNA vaccines. Due to the limited resource to SARS-CoV-2, we are 9

currently not able to re-challenge the vaccinated animals with an authentic virus. As the VSP platform 10 is based on lentiviral GagPol and no transfer vector is involved, it will not produce insertional and 11 replication competent lentiviruses. Additionally, the large-scale production and quality standard of 12 lentivirus that has been developed in CAR-T industry may facilitate the accessibility of VSP vaccine 13 to general populations. We further revealed the epitope profiles of vaccinated mice and the epitopes 14 susceptible to specific neutralizing antibodies, which may facilitate drug and antibody development. 

To detected spike mRNA numbers carried by VSP, total RNAs from all samples were extracted using 31 the Viral DNA/RNA extraction kit (TaKaRa) followed by cDNA synthesization using the HiScript 32 Q RT SuperMix for qPCR (Vazyme, China) according to the manufacturer's protocol. RT-qPCR was 1 performed using qPCR SYBR Green Master Mix (Vazyme) following the manufacturer's protocol. 2

Plasmid pLV-PGK-S-mut diluted into copies of 10 3 , 10 4 , 10 5 , 10 6 , 10 7 per microliter were used to 3 make a standard curve for absolute quantification. Primer sequences are as follows, forward primer: 4 5'-ACAGATGAGATGATCGCCCAG-3', reverse primer: 5'-TCTGCATGGCGAAAGGGATC-3'. A5 A6 S1_4 S1_8 S1_23 S1_24 S1_55 S1_57 S1_60 S1_76 S1_88 S1_96 S1_101 S1_102 S1_103 

A new coronavirus associated with human respiratory disease in China

Clinical course and risk factors for mortality of adult inpatients with COVID-4 19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in 6 Wuhan

Modified mRNA Vaccines Protect against Zika Virus Infection

Zika virus protection by a single low-dose nucleoside-modified mRNA 10 vaccination

The COVID-19 vaccine development landscape

Microneedle array delivered recombinant coronavirus vaccines: 14 Immunogenicity and rapid translational development

Rapid development of an inactivated vaccine candidate for SARS-CoV-2. 16

Vaccines: past, present and future

mRNA vaccines -a new era in 21 vaccinology

The outbreak of SARS-CoV-2 pneumonia calls for viral 23 vaccines

Virus-like particles as a highly efficient vaccine 25 platform: Diversity of targets and production systems and advances in clinical 26 development

Virus-like particles as immunogens

Development of a Novel Virus-Like Particle Vaccine Platform That 30 Mimics the Immature Form of Alphavirus

Preclinical 32 Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C

Potent neutralizing antibodies in the sera of convalescent COVID-19 35 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein. 36 bioRxiv

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 42 patient cohort and their implications. medRxiv

Immunogenicity and structures of a rationally designed prefusion MERS-1

Immunization delivered by lentiviral vectors for cancer and 3 infectious diseases

Why Glycosylation Matters in Building a Better Flu Vaccine. Molecular 5 &amp

Site-specific glycan 7 analysis of the SARS-CoV-2 spike

Protocol and reagents for pseudotyping lentiviral particles with 9 SARS-CoV-2 Spike protein for neutralization assays. bioRxiv

Exceptionally Potent Neutralization of Middle East Respiratory Syndrome 12 Coronavirus by Human Monoclonal Antibodies

Immune responses in COVID-19 and potential 14 vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac

Elevated exhaustion levels and reduced functional diversity of T cells in 17 peripheral blood may predict severe progression in COVID-19 patients

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Evaluation of the spike-11 specific cellular immune response stimulating with a spike peptide pool. g-i, Peptide microarray 12 analysis of epitopes. g, Representative images of spike protein peptide microarray

RBD were included in the microarray as controls. Highly frequent positive peptides were labeled

Signal intensity was averaged 15 fluorescent intensity of tinplated spots for each array. i Heatmap of antibody responses against 16

Analysing the epitopes of ShaCoVacc induced 17 spike-specific antibodies on spike protein. 6 mice used for each group, 1.5 µg ShaCoVacc or 50 µL 18 PBS were injected via footpad into each mouse. Error bars represent ±S.D. Unpaired two-tailed 19 student's t-tests